Qualigen is a biotechnology company committed to developing new therapeutics for adult and pediatric patients with rare cancers, as well as expansion of its flagship
FastPack® diagnostic platform. The FastPack® line of FDA-cleared and CE-Marked products has been used successfully in diagnostics since 2002.
Our therapeutics pipeline includes cancer drug compounds such as QN-247 (formerly referred to as AS1411-GNP or ALAN), and RAS-F, as well as STARS, a DNA/RNA-based treatment device.
| Indication | Stage |
|---|---|
Qualigen to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Read MoreQualigen to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Read MoreLD Micro Invitational XI Conference
Read MoreFirst Quarter 2021 Earnings Call
Read More